QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Grifols, S.A. (GRFS)

Healthcare

Actionable
Fundamental
3
Sentiment
3
Technical
4

Buy limit 8.45 — pullback to the 2026-11-09 session-low 8.44 / EMA9 8.38 support within an aligned uptrend (price above SMA20/50/200 and EMA9/21, ADX 30.81 rising, MACD 0.29 > signal 0.21 > 0) — with protective stop 8.20 (1.0xATR floor beneath the 8.26 two-session structural low), targets 8.95/9.33 and R/R 2.00; every Step-00 gate passed (price 8.69 <= 25, fundamentalScore 3, qualitativeScore 3, avgDollarVolume20 $6.39M, recent 3-session ~$7.0M, max overnight gap 2.12%, all indicators loaded, no event inside the window through 2026-12-02, ATR 2.88% of price); the alternative breakout buy-stop above the settled 8.82 high was evaluated and rejected on R/R (0.79 < 1.0).

Analysis as of 2026-11-10· more than 2 trading days ago

Company overview

Grifols, S.A., headquartered in Barcelona, Spain, develops, manufactures, and distributes therapeutic products primarily derived from human plasma. It operates through divisions focused on bioscience, hospital products, diagnostics, and bio supplies, serving healthcare providers globally.

Fundamental

fair
Fundamental3
Mixed improvement

Grifols shows improving fundamentals with deleveraging progress, but high leverage and governance concerns remain.

Grifols is a cash-generative, deleveraging plasma franchise trading at roughly ten times trailing per-share earnings and about seven-and-a-half times EV/EBITDA, with improving 2026 momentum, a mid-teens free-cash-flow yield and a refinanced maturity profile — offset by high absolute leverage, sub-cost-of-capital returns, goodwill impairment sensitivity in Diagnostics and governance/related-party overhangs. Mixed risk-reward: improving, but not yet de-risked.

Sentiment

fair
Sentiment3
Neutral sentiment

Sentiment is neutral with no significant media or retail activity, and a clean legal screen.

Q3 2026 results (announced, 2026-11-02) are the dominant catalyst: revenue came in above consensus on immunoglobulin demand with profit up 27.9% and margin expansion pushing covenant net leverage to 3.98x from 5.1x, though coverage flags one declining revenue stream, lingering debt questions, and a share price that has trailed the print. The delta is determinate but item-level (moderate confidence) — a flat measured baseline (polarity_score ≈ -0.01 across six scored items) giving way to a mildly positive in-window reception, with the scoring-window aggregate unavailable after an enrichment timeout — and the Red-Flag Screen is clean, so no cap applies.

Technical

good
Technical4
Strong uptrend

Technicals show a strong uptrend with aligned indicators and a pullback-to-support setup.

GRFS is in an aligned uptrend: price 8.69 sits above the SMA20 (7.94), SMA50 (7.67), SMA200 (7.99), EMA9 (8.38), EMA21 (8.07) and the 8.62 daily VWAP; ADX14 30.81 is rising from 13.46 over the two-week window; MACD line 0.29 is above signal 0.21 and above zero; and the 2026-11-09 session closed +3.1% on 1,186,200 shares (roughly double the 610,345 of the prior session) after printing an 8.82 high that cleared the 8.72 consolidation top intraday. Momentum is overbought (RSI14 72.77, Williams %R -8.97) and price is ~3.7% above the EMA9, so the tradeable structure is a dip-buy limit at the 8.44 session-low support rather than a chase; the buy-stop breakout alternative above the settled 8.82 high is rejected because its structure-based stop beneath the two-session floor of 8.26 yields R/R 0.79 (< 1.0). Score 4: multiple bullish confirmations across trend, momentum and volume, with overbought extension as the one weak signal.

You’re looking at 2026-11-10 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.